Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Michael Curtis

Plastic Surgery Saint Louis, MO Medical Doctor

NPI 1356543714 CMS profile 107383

701 S New Ballas Rd Ste 310, Saint Louis, MO 63141

Open in the dashboard

General payments

$21,381

99 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Michael Curtis of Saint Louis, MO is reported in the CMS Open Payments database as having received $21,381 across 99 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 90th percentile of Plastic Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $13,860 24
2024 General $2,222 19
2023 General $616 11
2022 General $1,116 6
2021 General $248 3
2020 General $239 3
2019 General $3,080 33

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Michael Curtis
  • Plastic Surgery median
  • Middle half of Plastic Surgery
  • National median

In program year 2025, general payments to Michael Curtis were reported at $13,860. Among 3,701 Plastic Surgery profiles paid that year, the median was $379 and the middle half received between $138 and $1,100.

Show as a table
Year Michael Curtis Plastic Surgery median Middle half National median
2019 $3,080 $371 $122–$1,483 $163
2020 $239 $158 $52–$438 $114
2021 $248 $249 $87–$752 $132
2022 $1,116 $274 $102–$793 $149
2023 $616 $299 $113–$891 $160
2024 $2,222 $361 $124–$1,062 $164
2025 $13,860 $379 $138–$1,100 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $14,758 31 payments
  2. Allergan Inc. $3,239 34 payments
  3. RTI Surgical, Inc $1,859 17 payments
  4. Stryker Corporation $655 1 payment
  5. Motiva USA, LLC $375 4 payments
  6. Derma Sciences, Inc. $130 1 payment
  7. Mentor Worldwide LLC $122 2 payments
  8. Vioptix Inc $106 2 payments
  9. Ethicon US, LLC $33 1 payment
  10. Integra LifeSciences Corporation $23 1 payment
  11. Other $81 5 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $11,354 4 payments
  2. Food and Beverage $6,083 87 payments
  3. Travel and Lodging $3,944 8 payments
Products named General payments · program years 2019–2025
  1. NATRELLE SALINE-FILLED BREAST IMPLANTS $15,142 24 payments
  2. ALLODERM $7,712 24 payments
  3. REVOLVE $6,839 6 payments
  4. STRATTICE RECONSTRUCTIVE TISSUE MATRIX BPS $6,839 6 payments
  5. CORTIVA ALLOGRAFT DERMIS $1,511 14 payments
  6. NATRELLE $886 13 payments
  7. SPY-PHI SYSTEM $655 1 payment
  8. FORTIVA PORCINE DERMIS $347 3 payments
  9. Motiva Implant Matrix Devices $216 3 payments
  10. Motiva Implant Matrix Plastic Surgery $159 1 payment
  11. Other $1,655 34 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 4 drugs

Part D claims

123

Median for Plastic and Reconstructive Surgery: 61

Drug cost

$661

Median for Plastic and Reconstructive Surgery: $369

Branded share of claims

31.7%

Median for Plastic and Reconstructive Surgery: 30%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 39 $221
Cefadroxil Generic 32 $174
Doxycycline Hyclate Generic 22 $148
Oxycodone Hcl Generic 30 $119

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 2,638 Part D prescribers listed as Plastic and Reconstructive Surgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 36 billing codes

Paid by Medicare

$35,261

Medicare's payments for the services billed

Medicare patients

61

Average age 70

Services billed

131

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Cancer 75%
High blood pressure 69%
Arthritis 59%
Depression 46%
Osteoporosis 28%
Diabetes 26%
Chronic kidney disease 20%
COPD 18%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

99 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Plastic Surgery in Missouri

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record